Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sonya Tran

Obstetrics & Gynecology Omaha, NE Medical Doctor

NPI 1669544615 CMS profile 724306

7205 W Center Rd, Ste 200, Omaha, NE 68124

Open in the dashboard

General payments

$3,410

200 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sonya Tran of Omaha, NE is reported in the CMS Open Payments database as having received $3,410 across 200 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $535 24
2024 General $624 34
2023 General $373 31
2022 General $584 37
2021 General $468 31
2020 General $248 18
2019 General $579 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sonya Tran
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Sonya Tran were reported at $535. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Sonya Tran Obstetrics & Gynecology median Middle half National median
2019 $579 $172 $62–$391 $163
2020 $248 $94 $36–$222 $114
2021 $468 $136 $42–$369 $132
2022 $584 $160 $50–$433 $149
2023 $373 $169 $56–$423 $160
2024 $624 $152 $50–$371 $164
2025 $535 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $778 55 payments
  2. Sumitomo Pharma America, Inc. $332 15 payments
  3. Daiichi Sankyo Inc. $254 15 payments
  4. Hologic, LLC $219 6 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $163 11 payments
  6. Organon LLC $161 12 payments
  7. Mayne Pharma Inc. $149 11 payments
  8. GlaxoSmithKline, LLC. $133 2 payments
  9. CooperSurgical, Inc. $125 7 payments
  10. TherapeuticsMD, Inc. $108 7 payments
  11. Other $987 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,384 198 payments
  2. Education $26 2 payments
Products named General payments · program years 2019–2025
  1. LO LOESTRIN FE $361 29 payments
  2. INJECTAFER $242 14 payments
  3. MYFEMBREE Hormone Therapy $231 11 payments
  4. LILETTA $221 13 payments
  5. ORILISSA $195 15 payments
  6. ORIAHNN $161 10 payments
  7. SHINGRIX $133 2 payments
  8. Sexually Transmitted Infectious Disease $124 1 payment
  9. Kyleena $116 8 payments
  10. MYFEMBREE Womens Health $116 5 payments
  11. Other $2,187 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$2,743

Medicare's payments for the services billed

Medicare patients

31

Average age 70

Services billed

58

31 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 45%
Arthritis 42%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $155
$155 — —
INJECTAFER
  • Daiichi Sankyo Inc. $81
$81 — —
Wegovy
  • Novo Nordisk Inc $29
$29 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $23
$23 — —
NP Thyroid 60
  • Acella Pharmaceuticals, LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record